Ratings DRI Healthcare Trust

Equities

DHT.U

CA23344H1091

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-04-26 pm EDT			5-day change	1st Jan Change
16.36 ^CAD	-1.09%		-2.85%	+31.09%

Apr. 23	DRI Healthcare Trust Brief: Adds Transaction "Significantly" Reduces Potential Dilution With a Net Reduction of Warrants Equivalent to 8.2% of Units Outstanding	MT
Apr. 23	DRI Healthcare Trust Brief: Says Closed Prior Announced Refinancing of Preferred Securities	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company is in a robust financial situation considering its net cash and margin position.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's earnings growth outlook lacks momentum and is a weakness.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 77.9 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
DRI HEALTHCARE TRUST	+31.09%	674M	-
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes